Aldo José Peixoto
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Aldo José Peixoto has a total of 103 co-authors. Here are the top co-authors by number of shared publications:
- Chirag R. Parikh
Division of Nephrology, Johns Hopkins University, Baltimore, Maryland, USA
5 shared publications Marcelo Orias
Nephrology Service, Sanatorio Allende
3 shared publicationsSergio F. F. Santos
Division of Nephrology, State University of Rio de Janeiro, Rio de Janeiro, RJ, Brazil
3 shared publications- Ana Elizabeth Figueiredo
Pontifícia Universidade Católica do Rio Grande do Sul
2 shared publications - Ana Flávia Moura
Sociedade Brasileira de Nefrologia
2 shared publications - Audes Diógenes Magalhães Feitosa
Pronto Socorro Cardiológico de Pernambuco (PROCAPE), University of Pernambuco , Rua dos Palmares, s/n, Santo Amaro, Recife, PE CEP 50100-060
2 shared publications
Latest Publications
- Open Access
- 1 March 2025
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Nephrology
- Vol. 47 (1) , e20240033
I Diretriz Brasileira de hipertensão arterial na diálise da Sociedade Brasileira de Nefrologia
Resumo A hipertensão arterial em pacientes em diálise (HAD) tem alta prevalência, de pelo menos 80% ou mais, e seu manejo na prática do nefrologista ocorre de forma heterogênea e, frequentemente, empírica. Saber definir, conhecer a fisiopatologia, diagnosticar, acompanhar e tratar com mudanças no estilo de vida, e adequar os medicamentos anti-hipertensivos para alcançar a meta de pressão arterial (PA) recomendada, com vistas à redução da morbidade e mortalidade, requerem conhecimentos e abordagens específicos nos contextos da hemodiálise (HD) e da diálise peritoneal (DP). Este documento é a primeira diretriz da Sociedade Brasileira de Nefrologia, elaborada pelos departamentos de Hipertensão e de Diálise, que visa orientar os médicos que prestam assistência em centros de diálise a como manejar pacientes com HAD, de forma integral e individualizada, com base no julgamento crítico das melhores evidências científicas disponíveis e, quando essas são escassas ou indisponíveis, indicar a opinião de especialistas. Os diferentes temas abordados envolvem: a definição (PA pré-HD ≥ 140/90 mmHg e PA pós-HD ≥ 130/80 mmHg), epidemiologia e fisiopatologia; diagnóstico da HAD preferencialmente com medidas da PA fora do ambiente de diálise (PA ≥ 130/80 mmHg); avaliação complementar; metas pressóricas; tratamento não medicamentoso; uso dos anti-hipertensivos mais adequados; situações especiais; e complicações da HAD, predominantemente as cardiovasculares.
- 1 March 2025
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Nephrology
- Vol. 47 (1) , e20240033
Open AccessI Diretriz Brasileira de hipertensão arterial na diálise da Sociedade Brasileira de Nefrologia
Resumo A hipertensão arterial em pacientes em diálise (HAD) tem alta prevalência, de pelo menos 80% ou mais, e seu manejo na prática do nefrologista ocorre de forma heterogênea e, frequentemente, empírica. Saber definir, conhecer a fisiopatologia, diagnosticar, acompanhar e tratar com mudanças no estilo de vida, e adequar os medicamentos anti-hipertensivos para alcançar a meta de pressão arterial (PA) recomendada, com vistas à redução da morbidade e mortalidade, requerem conhecimentos e abordagens específicos nos contextos da hemodiálise (HD) e da diálise peritoneal (DP). Este documento é a primeira diretriz da Sociedade Brasileira de Nefrologia, elaborada pelos departamentos de Hipertensão e de Diálise, que visa orientar os médicos que prestam assistência em centros de diálise a como manejar pacientes com HAD, de forma integral e individualizada, com base no julgamento crítico das melhores evidências científicas disponíveis e, quando essas são escassas ou indisponíveis, indicar a opinião de especialistas. Os diferentes temas abordados envolvem: a definição (PA pré-HD ≥ 140/90 mmHg e PA pós-HD ≥ 130/80 mmHg), epidemiologia e fisiopatologia; diagnóstico da HAD preferencialmente com medidas da PA fora do ambiente de diálise (PA ≥ 130/80 mmHg); avaliação complementar; metas pressóricas; tratamento não medicamentoso; uso dos anti-hipertensivos mais adequados; situações especiais; e complicações da HAD, predominantemente as cardiovasculares.
- Open Access
- 1 March 2025
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Nephrology
- Vol. 47 (1) , e20240033
I Brazilian guideline on hypertension in dialysis of the Brazilian Society of Nephrology
Hypertension in dialysis patients (HTND) has a high prevalence, affecting at least 80% or more of patients, and its management in the nephrology practice is heterogeneous and often empirical. Knowing how to define, understand the pathophysiology, diagnose, monitor and treat with lifestyle changes, and adjust antihypertensive drugs to achieve the recommended blood pressure (BP) target - to reduce morbidity and mortality - requires specific knowledge and approaches within the contexts of hemodialysis (HD) and peritoneal dialysis (PD). This document is the first guideline of the Brazilian Society of Nephrology, developed by the departments of Hypertension and Dialysis. It aims to guide physicians who provide care in dialysis centers on how to manage patients with HTND, in a comprehensive and individualized manner, based on the critical appraisal of the best available scientific evidence. When such evidence is scarce or unavailable, the opinion of specialists should be recommended. The different topics covered include HTND definition (pre-HD BP ≥ 140/90 mmHg and post-HD BP ≥ 130/80 mmHg), epidemiology, and pathophysiology; diagnosis of HTND preferably with BP measurements outside the dialysis setting (BP ≥ 130/80 mmHg); complementary assessment; blood pressure targets; non-pharmacological treatment; use of the most appropriate antihypertensive medications; special situations; and complications of HTND, predominantly cardiovascular ones.
- 1 March 2025
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Nephrology
- Vol. 47 (1) , e20240033
Open AccessI Brazilian guideline on hypertension in dialysis of the Brazilian Society of Nephrology
Hypertension in dialysis patients (HTND) has a high prevalence, affecting at least 80% or more of patients, and its management in the nephrology practice is heterogeneous and often empirical. Knowing how to define, understand the pathophysiology, diagnose, monitor and treat with lifestyle changes, and adjust antihypertensive drugs to achieve the recommended blood pressure (BP) target - to reduce morbidity and mortality - requires specific knowledge and approaches within the contexts of hemodialysis (HD) and peritoneal dialysis (PD). This document is the first guideline of the Brazilian Society of Nephrology, developed by the departments of Hypertension and Dialysis. It aims to guide physicians who provide care in dialysis centers on how to manage patients with HTND, in a comprehensive and individualized manner, based on the critical appraisal of the best available scientific evidence. When such evidence is scarce or unavailable, the opinion of specialists should be recommended. The different topics covered include HTND definition (pre-HD BP ≥ 140/90 mmHg and post-HD BP ≥ 130/80 mmHg), epidemiology, and pathophysiology; diagnosis of HTND preferably with BP measurements outside the dialysis setting (BP ≥ 130/80 mmHg); complementary assessment; blood pressure targets; non-pharmacological treatment; use of the most appropriate antihypertensive medications; special situations; and complications of HTND, predominantly cardiovascular ones.
- Open Access
- 17 January 2022
- Published by Oxford University Press (OUP) in American Journal of Hypertension
- Vol. 35 (5) , 433-440
Excessive Blood Pressure Response to Clonidine in Hospitalized Patients With Asymptomatic Severe Hypertension
There are limited and nonconcordant data on the rapidity and safety of blood pressure response to clonidine in the setting of asymptomatic severe hypertension. We evaluated the blood pressure response to clonidine in hospitalized patients with asymptomatic severe hypertension. We performed a review of hospitalized, noncritically ill patients receiving clonidine within 6 hours of developing asymptomatic severe hypertension (systolic blood pressure [SBP] >180 or diastolic blood pressure [DBP] >110 mm Hg in the absence of acute hypertension-mediated target organ damage). The incidence of mean arterial pressure (MAP) reduction by ≥30% at 4 hours after clonidine was the primary endpoint. We identified 200 relevant patient encounters (median age 63 years, 48.5% women). Median time to clonidine following asymptomatic severe hypertension was 2.8 hours. A total of 20 (10%) patients had ≥30% MAP reduction within 4 hours after clonidine, and 32 (16%) patients had ≥30% reduction in either SBP, DBP, or MAP. Older age, female sex, and preexisting vascular disease were associated with ≥30% MAP reductions (P < 0.05). Only patient sex and clonidine dose of 0.3 mg were significant in multivariable models. There were 14 adverse events observed within 24 hours of administration of clonidine; most (9) were acute kidney injury. There were no ischemic (myocardial, cerebrovascular) events. A substantial minority of hospitalized patients with asymptomatic severe hypertension experience precipitous blood pressure decline with clonidine, and though blood pressure declines more precipitously in women and those receiving higher doses (0.3 mg specifically), the response to clonidine is generally not predictable on clinical grounds.
- 17 January 2022
- Published by Oxford University Press (OUP) in American Journal of Hypertension
- Vol. 35 (5) , 433-440
Open AccessExcessive Blood Pressure Response to Clonidine in Hospitalized Patients With Asymptomatic Severe Hypertension
There are limited and nonconcordant data on the rapidity and safety of blood pressure response to clonidine in the setting of asymptomatic severe hypertension. We evaluated the blood pressure response to clonidine in hospitalized patients with asymptomatic severe hypertension. We performed a review of hospitalized, noncritically ill patients receiving clonidine within 6 hours of developing asymptomatic severe hypertension (systolic blood pressure [SBP] >180 or diastolic blood pressure [DBP] >110 mm Hg in the absence of acute hypertension-mediated target organ damage). The incidence of mean arterial pressure (MAP) reduction by ≥30% at 4 hours after clonidine was the primary endpoint. We identified 200 relevant patient encounters (median age 63 years, 48.5% women). Median time to clonidine following asymptomatic severe hypertension was 2.8 hours. A total of 20 (10%) patients had ≥30% MAP reduction within 4 hours after clonidine, and 32 (16%) patients had ≥30% reduction in either SBP, DBP, or MAP. Older age, female sex, and preexisting vascular disease were associated with ≥30% MAP reductions (P < 0.05). Only patient sex and clonidine dose of 0.3 mg were significant in multivariable models. There were 14 adverse events observed within 24 hours of administration of clonidine; most (9) were acute kidney injury. There were no ischemic (myocardial, cerebrovascular) events. A substantial minority of hospitalized patients with asymptomatic severe hypertension experience precipitous blood pressure decline with clonidine, and though blood pressure declines more precipitously in women and those receiving higher doses (0.3 mg specifically), the response to clonidine is generally not predictable on clinical grounds.
- 4 January 2022
- Published by Cleveland Clinic Journal of Medicine in Cleveland Clinic Journal of Medicine
- Vol. 89 (1) , 36-45
Evaluation and management of orthostatic hypotension: Limited data, limitless opportunity
Orthostatic hypotension is common and can have serious consequences. The author offers a systematic approach to evaluation and management.
- 4 January 2022
- Published by Cleveland Clinic Journal of Medicine in Cleveland Clinic Journal of Medicine
- Vol. 89 (1) , 36-45
Evaluation and management of orthostatic hypotension: Limited data, limitless opportunity
Orthostatic hypotension is common and can have serious consequences. The author offers a systematic approach to evaluation and management.
- 25 August 2020
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 15 (9) , 1237-1239
Arterial Mechanics following Living Kidney Donation
- 25 August 2020
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 15 (9) , 1237-1239
Arterial Mechanics following Living Kidney Donation
- Open Access
- 30 January 2020
- Published by Wolters Kluwer Health in Kidney360
- Vol. 1 (1) , 9-13
Is There a Role for Device Therapies in Resistant Hypertension?
- 30 January 2020
- Published by Wolters Kluwer Health in Kidney360
- Vol. 1 (1) , 9-13
Open AccessIs There a Role for Device Therapies in Resistant Hypertension?
- Open Access
- 17 October 2019
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 7 (1) , 262
Seronegative autoimmune autonomic ganglionopathy from dual immune checkpoint inhibition in a patient with metastatic melanoma
Background Immune checkpoint inhibitors have improved clinical outcomes including survival in several malignancies but have also been associated with a range of immune-related adverse events (irAEs). Neurological irAEs are rare compared to the more typical skin, gastrointestinal, and endocrine toxicities, and are often underrecognized and challenging to diagnose. Here, we report a case of seronegative autoimmune autonomic ganglionopathy (AAG) induced by dual immune checkpoint inhibitor therapy (ICI) in a patient with metastatic melanoma. Case presentation A patient with metastatic melanoma was treated with ipilimumab and nivolumab. He developed a constellation of new symptoms including nausea, fatigue, and severe orthostatic hypotension refractory to fluid resuscitation. An infectious, cardiac, neurologic, and endocrine workup were unrevealing. Cardiovascular autonomic testing revealed poor sympathetic nervous system responses. He was diagnosed with seronegative AAG and significantly improved with immunomodulatory therapies including IVIG and steroids as well as varying doses of midodrine and fludrocortisone. He was able to restart nivolumab without recurrence of his symptoms. However, the AAG reoccurred when he was re-challenged with ipilimumab and nivolumab due to disease progression. While the AAG was manageable with steroids at that time, unfortunately his melanoma became resistant to ICI. Conclusions Immune checkpoint inhibitors can have a wide range of unusual, rare irAEs, including neurotoxicity such as AAG. Clinicians should maintain suspicion for this toxicity so that treatment can be rapidly provided to avoid disability.
- 17 October 2019
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 7 (1) , 262
Open AccessSeronegative autoimmune autonomic ganglionopathy from dual immune checkpoint inhibition in a patient with metastatic melanoma
Background Immune checkpoint inhibitors have improved clinical outcomes including survival in several malignancies but have also been associated with a range of immune-related adverse events (irAEs). Neurological irAEs are rare compared to the more typical skin, gastrointestinal, and endocrine toxicities, and are often underrecognized and challenging to diagnose. Here, we report a case of seronegative autoimmune autonomic ganglionopathy (AAG) induced by dual immune checkpoint inhibitor therapy (ICI) in a patient with metastatic melanoma. Case presentation A patient with metastatic melanoma was treated with ipilimumab and nivolumab. He developed a constellation of new symptoms including nausea, fatigue, and severe orthostatic hypotension refractory to fluid resuscitation. An infectious, cardiac, neurologic, and endocrine workup were unrevealing. Cardiovascular autonomic testing revealed poor sympathetic nervous system responses. He was diagnosed with seronegative AAG and significantly improved with immunomodulatory therapies including IVIG and steroids as well as varying doses of midodrine and fludrocortisone. He was able to restart nivolumab without recurrence of his symptoms. However, the AAG reoccurred when he was re-challenged with ipilimumab and nivolumab due to disease progression. While the AAG was manageable with steroids at that time, unfortunately his melanoma became resistant to ICI. Conclusions Immune checkpoint inhibitors can have a wide range of unusual, rare irAEs, including neurotoxicity such as AAG. Clinicians should maintain suspicion for this toxicity so that treatment can be rapidly provided to avoid disability.
- 1 October 2017
- Published by Elsevier in Kidney International
- Vol. 92 (4) , 816-823
Blood pressure targets for hemodialysis patients
- 1 October 2017
- Published by Elsevier in Kidney International
- Vol. 92 (4) , 816-823
Blood pressure targets for hemodialysis patients
- 13 October 2016
- Published by Springer Nature
- p. 15-33
Assessment of Hypertension in Chronic Kidney Disease
- 13 October 2016
- Published by Springer Nature
- p. 15-33
Assessment of Hypertension in Chronic Kidney Disease
- 1 July 2016
- Published by Elsevier in Advances in Chronic Kidney Disease
- Vol. 23 (4) , 255-261
Hypertension Management in Transition: From CKD to ESRD
- 1 July 2016
- Published by Elsevier in Advances in Chronic Kidney Disease
- Vol. 23 (4) , 255-261
Hypertension Management in Transition: From CKD to ESRD